Patient access schemes for high-cost cancer medicines

The Lancet Oncology

Volumn 11, Issue 2, 2010, Pages 111-112

  Williamson, Steve ^a  

^a NORTH TYNESIDE GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CETUXIMAB; ERLOTINIB; SUNITINIB;

CANCER THERAPY; COLORECTAL CANCER; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG RESPONSE; GASTROINTESTINAL STROMAL TUMOR; HEALTH CARE ACCESS; HEALTH CARE COST; HUMAN; KIDNEY CANCER; LETTER; LUNG CANCER; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NATIONAL HEALTH SERVICE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REIMBURSEMENT; UNITED KINGDOM;

ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; GREAT BRITAIN; HEALTH SERVICES ACCESSIBILITY; HUMANS; NEOPLASMS;

EID: 75249090323     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70402-4     Document Type: Letter

References (7)

1. Taylor L. Patient access schemes: a battle for hearts and minds. Pharmatimes (September 2009) 26-27
2. Department of Health. The Pharmaceutical Price Regulation Scheme. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/DH_091825 (accessed Jan 4, 2010).
3. National Institute of Clinical Excellence (NICE). TA129 Bortezomib for relapsed multiple myeloma; issue date October 2007. http://www.nice.org.uk/TA129 (accessed Jan 4, 2010).
4. Pickin M., Cooper C.L., Chater T., et al. The Multiple Sclerosis Risk Sharing Scheme Monitoring Study-early results and lessons for the future. BMC Neurology 9 (2009) 1
5. Wynd K. Risk sharing schemes-improving patient access to new drugs. Hospital Pharmacist 15 (2008) 114
6. Williamson S., and Thomson D. Debate: do risk share schemes cause more problems than they solve?. Br J Clin Pharmacy 1 (2009) 54-55
7. House of Commons Health Committee. Top-up fees fourth report of session 2008-09. HC 194-I published on May 12, 2009. http://www.publications.parliament.uk/pa/cm200809/cmselect/cmhealth/194i/194i.pdf (accessed Jan 4, 2010).